Randomized controlled trials of liraglutide and sitagliptin in obese patients with inadequately controlled type 2 diabetes with insulin therapy

Abstract

Objective To investigate the efficacy of liraglutide and sitagliptin on obese patients with inadequately controlled type 2 diabetes with insulin therapy. Methods One hundred and six patients with obesity and type 2 diabetes mellitus were treated by insulin therapy from February 2015 to January 2016, according to the order of admission, they were divided into study group and control group, with 53 cases in each group. The control group was treated with sitagliptin, and the study group was treated with liraglutide. The body weight and waist circumference, blood pressure, blood glucase levels and blood lipid levels before and after treatment were compared, also the incidences of adverse reactions in the two groups were analyzed. Results There was no significant difference in body weight or waist circumference between the two groups before treatment (P>0.05); after treatment, the indicators of the study group were significantly lower than before treatment, the control group had no significant change, the differences between the two groups were significant (P 0.05); after treatment, the index of the two groups improved compared with those before treatment, and the systolic blood pressure level of study group was significantly better than that of control group, the differences were significant (P 0.05); after treatment, the indexes of the two groups were significantly improved compared with those before treatment (P 0.05). The incidence of adverse reactions was 26.46% in the study group and 5.67% in the control group, and there was significant difference between the two groups (P<0.05). Conclusions Both liraglutide and sitagliptin has significant hypoglycemic effect on obese patients with inadequately controlled type 2 diabetes with insulin therapy, and the effects of liraglutide improves systolic blood pressure, body weight and blood glucose level are better than those of sitagliptin, but the rate of gastrointestinal adverse reactions by liraglutide is higher. In clinical practice, the best treatment scheme should be selected according to the specific circumstances of the patients. Key words: Liraglutide; Sitagliptin; Insulin; Inadequately controlled; Obese; Type 2 diabetes mellitus